$INO Major Update on AZD7442 also being dMAb®-cloned by Ino Nov 30, 2021 14:25 PST DNA encoded monoclonal antibody (dMAb®) treatment for infectious disease and beyond. World Antiviral Congress - Room 4 Trevor Smith, VP of Preclinical Developments (was promoted 2021), Inovio Pharmaceuticals terrapinn.com/conference/wo... COVID-19 dMAb P1/P2 to start before 12/15/21. “The dMAb candidates will then be advanced into preclinical studies and then into rigorous, first-in-human clinical trials within one year of funding.” 12/15/20 11/21/21 London: A single shot of an antibody treatment against Covid-19 developed by UK drug major AstraZeneca is 83 per cent capable to reduce the risk of the infectious disease compared to placebo, according to new clinical trial results. The antibody treatment, known as AZD7442, has shown to be highly effective at preventing Covid-19 in people who may not respond well to vaccines, the company said in a statement.